Relative Bioavailability Study of HU6

Phase 1 Completed 43 enrolled Rivus Pharmaceuticals, Inc.

RandomizedCrossoverOpen-labelTreatment

Summary

This is a 2-part study. Part 1 will assess the relative bioavailability of the new 450 mg tablet test formulation compared to the 150 mg capsule reference formulation (3 x 150 mg). Part 1 dosing will be conducted in the fasted state. Part 2 will assess the effect of food (and fat content) on the pharmacokinetics of the 450 mg tablet test formulation.

Timeline

Start: 2024-07-24
Primary completion: 2024-11-15
Completion: 2024-12-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HU6	Unknown	450 mg	—

Indications

No indication recorded.